» Articles » PMID: 36943653

Combining Serum AFP and CEUS LI-RADS for Better Diagnostic Performance in Chinese High-risk Patients

Overview
Journal Radiol Med
Specialty Radiology
Date 2023 Mar 21
PMID 36943653
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To evaluate and compare the diagnostic performance of revised contrast-enhanced ultrasound (CEUS) Liver Imaging Reporting and Data System version by combining LR-M category and serum alpha-fetoprotein (AFP) under different cut-off values.

Material And Methods: This retrospective study enrolled 152 high-risk patients with 152 histology-proven nodules. For revised LI-RADS, nodules in LR-M with different elevated AFP thresholds have been reclassified as the LR-5 category. The diagnostic performances of original and revised CEUS LI-RADS were evaluated and compared.

Results: To compare with the original version, the sensitivity of revised LR-5 (adjusted with AFP value > 200 ng/ml or 400 ng/ml) for the diagnosis of hepatocellular carcinoma (HCC) improved from 52.5 to 69.2% or 65.0%, respectively (both p < 0.001) without compromising specificity (87.5% vs. 71.9% or 78.1%, respectively, both p > 0.05). For the diagnosis of non-HCC malignancy, the specificity of the LR-M after reclassification was improved (69.6% vs. 84.4% or 80.7%, respectively, both p < 0.001) with a non-significant sensitivity reduction (100.0 vs. 70.6% or 82.4%, respectively, both p > 0.05). After modification, the sensitivity of LR-5 also increased to 69.1% or 64.9% (both p < 0.001), while the specificity and PPV did not change (both p > 0.05) for larger nodules (> 20 mm).

Conclusion: The diagnostic performance of CEUS LI-RADS can be further improved by reclassifying LR-M nodules with elevated AFP thresholds to LR-5.

Citing Articles

Effect of combining serum alpha-fetoprotein with LI-RADS v2018 on gadoxetate-enhanced MRI in the diagnosis and prognostication of hepatocellular carcinoma.

Kim D, Choi S, Koo B, Choi S, Jang H, Heo S Eur Radiol. 2025; .

PMID: 39930127 DOI: 10.1007/s00330-025-11418-2.


All You Need to Know About TACE: A Comprehensive Review of Indications, Techniques, Efficacy, Limits, and Technical Advancement.

Lanza C, Ascenti V, Amato G, Pellegrino G, Triggiani S, Tintori J J Clin Med. 2025; 14(2).

PMID: 39860320 PMC: 11766109. DOI: 10.3390/jcm14020314.


Microwave ablation followed by cTACE in 5-cm HCC lesions: does a single-session approach affect liver function?.

Floridi C, Cacioppa L, Rossini N, Macchini M, Bruno A, Agostini A Radiol Med. 2024; 129(8):1252-1264.

PMID: 38958915 PMC: 11322225. DOI: 10.1007/s11547-024-01842-7.

References
1.
McGlynn K, Petrick J, London W . Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis. 2015; 19(2):223-38. PMC: 4712629. DOI: 10.1016/j.cld.2015.01.001. View

2.
Yang J, Hainaut P, Gores G, Amadou A, Plymoth A, Roberts L . A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019; 16(10):589-604. PMC: 6813818. DOI: 10.1038/s41575-019-0186-y. View

3.
Bridgewater J, Galle P, Khan S, Llovet J, Park J, Patel T . Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014; 60(6):1268-89. DOI: 10.1016/j.jhep.2014.01.021. View

4.
Froechlich G, Caiazza C, Gentile C, DAlise A, De Lucia M, Langone F . Integrity of the Antiviral STING-mediated DNA Sensing in Tumor Cells Is Required to Sustain the Immunotherapeutic Efficacy of Oncolytic Virus. Cancers (Basel). 2020; 12(11). PMC: 7698602. DOI: 10.3390/cancers12113407. View

5.
Claudon M, Dietrich C, Choi B, Cosgrove D, Kudo M, Nolsoe C . Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver--update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultraschall Med. 2012; 34(1):11-29. DOI: 10.1055/s-0032-1325499. View